An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bac...
Saved in:
Published in | Science (American Association for the Advancement of Science) Vol. 370; no. 6523; pp. 1473 - 1479 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The American Association for the Advancement of Science
18.12.2020
AAAS American Association for the Advancement of Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!